Coherus Bioscien Stock Price, News & Analysis

Coherus (CHRS) and Junshi Biosciences announced significant results from the JUPITER-02 study, a Phase 3 trial assessing toripalimab with chemotherapy for advanced nasopharyngeal carcinoma (NPC).

The trial revealed a median progression-free survival (PFS) of 21.4 months for the toripalimab group versus 8.2 months for placebo, showing a strong statistical significance. Interim overall survival (OS) data indicates a 41% reduced risk of death.

The FDA has granted breakthrough therapy designation for toripalimab, with a biologics license application currently under priority review.

Coherus BioSciences (NASDAQ: CHRS) announced on April 5, 2022, that it granted stock options for 461,000 shares to newly hired employees as of March 31, 2022. These options have an exercise price of $12.91, aligned with the closing price on the grant date. A Chief level executive received options for 200,000 shares and 50,000 restricted stock units, while 18 non-officer employees were awarded options for a total of 261,000 shares. This move aims to attract new talent under the 2016 Employment Commencement Incentive Plan approved by the Company’s board.

Coherus BioSciences, Inc. (CHRS) is positioning itself for long-term growth by targeting $1.2 billion in annual net sales by 2026. The company is advancing its immuno-oncology pipeline, focusing on its PD-1 inhibitor, toripalimab, which is under FDA review for nasopharyngeal carcinoma. Upcoming product launches include CIMERLI, a Lucentis biosimilar, and YUSIMRY, a Humira biosimilar. Coherus plans to leverage existing commercial infrastructure for these launches, aiming for significant shareholder value creation.

Coherus BioSciences (Nasdaq: CHRS) announced an Analyst Day set for March 29, 2022, at 9:30 a.m. ET in New York City. The event will focus on prospective product launches over the next 15 months, along with updates on the company’s entry into immuno-oncology with PD-1 inhibitor toripalimab and combination therapies. The FDA is reviewing toripalimab for nasopharyngeal carcinoma, with a decision expected by April 30, 2022. Additionally, Coherus plans to launch its Humira biosimilar in 2023 and is pursuing various biosimilars in development.

Coherus BioSciences has appointed Dr. Rosh Dias as Chief Medical Officer, enhancing its leadership at a critical time for upcoming product launches. Dr. Dias, with over 20 years in the biotech sector, has experience in oncology and immuno-oncology. Coherus is preparing to launch several products, including toripalimab, currently under FDA review with a target action date of April 30, 2022. The company intends to utilize cash generated from its existing biosimilars to fund its immuno-oncology initiatives, positioning itself as a leader in innovative therapies for cancer treatment.

Junshi Biosciences and Coherus BioSciences announced positive results from the pivotal CHOICE-01 Phase 3 clinical trial of toripalimab plus chemotherapy for advanced non-small cell lung cancer (NSCLC) patients without EGFR/ALK mutations. The trial met its primary endpoint of progression-free survival (PFS) and a secondary endpoint of overall survival (OS), showing a median PFS of 8.4 months versus 5.6 months with chemotherapy alone (HR=0.49). The study revealed a manageable safety profile and the potential for future trials based on biomarker data. The FDA has granted priority review for toripalimab.

Coherus BioSciences (Nasdaq: CHRS) announced its participation in two key investor conferences in March 2022. The 42nd Annual Cowen Health Care Conference will take place on March 9 at 10:30 a.m. ET, followed by the Barclays Global Healthcare Conference on March 15 at 2:35 p.m. ET. Audio webcasts of both presentations will be available on the investors' section of Coherus' website and will remain archived for 30 days. Investors are encouraged to access the site beforehand for a timely connection.

Coherus BioSciences (CHRS) and Junshi Biosciences announced the publication of results from the JUPITER-06 trial demonstrating that toripalimab combined with chemotherapy significantly improves progression-free survival (PFS) and overall survival (OS) in patients with advanced esophageal squamous cell carcinoma (ESCC). The trial, which involved 514 treatment-naïve patients, showed median OS at 17 months (toripalimab) versus 11 months (placebo), with a hazard ratio of 0.58. Notably, benefits were observed across all PD-L1 expression subgroups, including those with low expression.

Coherus BioSciences (NASDAQ: CHRS) reported Q4 and FY 2021 results, highlighting a net revenue of $73 million in Q4 and $327 million for the year, reflecting declines attributed to increased competition and COVID-19 impacts. The FDA approved YUSIMRY, with a projected launch in 2023, and toripalimab's BLA received priority review for nasopharyngeal carcinoma. The company aims for further diversification with the anticipated launch of CIMERLI. Financial guidance for 2022 estimates combined R&D and SG&A expenses between $415 million and $450 million, coupled with significant projected losses.